Search Results - "Verheul, H.M"

The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms by Caponi, S., Funel, N., Frampton, A.E., Mosca, F., Santarpia, L., Van der Velde, A.G., Jiao, L.R., De Lio, N., Falcone, A., Kazemier, G., Meijer, G.A., Verheul, H.M., Vasile, E., Peters, G.J., Boggi, U., Giovannetti, E.

“…This multicenter study evaluated three candidate microRNAs (miRNAs) (miR-21, miR-155 and miR-101) as potential biomarkers in intraductal papillary mucinous…”
Get full text

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry by Honeywell, R., Yarzadah, K., Giovannetti, E., Losekoot, N., Smit, E.F., Walraven, M., Lind, J.S.W., Tibaldi, C., Verheul, H.M., Peters, G.J.

“…A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed…”
Get full text

Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells by Giovannetti, E, Labots, M, Dekker, H, Galvani, E, Lind, J S W, Sciarrillo, R, Honeywell, R, Smit, E F, Verheul, H M, Peters, G J

“…Combination of drugs with different targets is a logical approach to overcome multilevel cross-stimulation among key pathways in NSCLC progression such as…”
Get more information

MON-PP095: Muscle Wasting of ≥10% During Chemotherapy is Independently Associated with Survival by Blauwhoff-Buskermolen, S, Versteeg, K.S, de van der Schueren, M.A, den Braver, N.R, Berkhof, H.J, Langius, J.A, Verheul, H.M

Get full text

OR017: The Assessment of Anorexia in Patients with Cancer: Cut-Off Values for the FAACT-A/CS and the Vas for Appetite by Blauwhoff-Buskermolen, S, Ruijgrok, C, Ostelo, R.W, de Vet, H.C, Verheul, H.M, de van der Schueren, M.A, Langius, J.A

Get full text

Chromosome 18q11.2 loss as a predictive marker for response to bevacizumab in metastatic colorectal cancer by Ylstra, B, Cordes, M, Biesma, H.D, Verheul, H.M, Neerincx, M, Koopman, M, Punt, C.J, Meijer, G.A, Murphy, V, Barat, A, Betge, J, Ebert, M, Gaiser, T, Fender, B, Klinger, R, Das, S, Smeets, D, Lambrechts, D, Byrne, A.T, Van Grieken, N.C.T

“…An abstract of the study by Ylstra et al identifying copy number abberations that are associated with response to bevacizumab is presented. In the study within…”
Get full text

PO-0955: Improving the radio-sensitizing effect of sunitinib by drug-specific scheduling by Kleibeuker, E, Castricum, K.C, Ten Hooven, M, Van den Berg, J, Griffioen, A.W, Slotman, B.J, Verheul, H.M, Thijssen, V.L

Get full text

Towards an objective longitudinal assessment of oncogeriatric outpatients by Slee-Valentijn, M.S, Versteeg, K.S, Maier, A.B, Verheul, H.M, Konings, I.R

Get full text

Sarcopenia is prevalent in more than half of older and younger patients with cancer by Versteeg, K.S, Blauwhoff-Buskermolen, S, van Bokhorst- de van der Schueren, M.A, Langius, J.A, Maier, A.B, Konings, I.R, Verheul, H.M

Get full text

Improving visualization and adherence by converting the Dutch colorectal cancer guidelines into decision trees: The Oncoguide project by van Oijen, M.G., Verbeek, X.A., van Vegchel, T., Nagtegaal, I.D., Lahaye, M.J., Méndez Romero, A., Rütten, H., de Bruijn, S., Verheul, H.M., Tanis, P.J., Punt, C.J.A., Keikes, L.

Get full text

ReCab II: A phase II trial of Cabazitaxel +/- Rhenium -188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment by Bouman-Wammes, E., van Dodewaard-De Jong, J.M., Bloemendal, H., Verheul, H.M., de Klerk, J.M.H., van den Eertwegh, A.J.M.

Get full text

Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials by Mau-Sorensen, M., van Bussel, M., Kuipers, M., Nielsen, D.L., Verheul, H.M., Aftimos, P., de Jonge, M.J.A., van Triest, B., Falkenius, J., Debus, J., Troost, E., Samuels, M., Sarholz, B., Budach, V., Goel, S., Locatelli, G., Geertsen, P.F.

Get full text

66 - Chromosome 18q11.2 loss as a predictive marker for response to bevacizumab in metastatic colorectal cancer by Ylstra, B., Cordes, M., Biesma, H.D., Verheul, H.M., Neerincx, M., Koopman, M., Punt, C.J., Meijer, G.A., Murphy, V., Barat, A., Betge, J., Ebert, M., Gaiser, T., Fender, B., Klinger, R., Das, S., Smeets, D., Lambrechts, D., Byrne, A.T., Van Grieken, N.C.T.

Get full text

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma by Moek, K L, Fiedler, W M, von Einem, J C, Verheul, H M, Seufferlein, T, de Groot, D J, Heinemann, V, Kebenko, M, Menke-van der Houven van Oordt, C W, Ettrich, T J, Rasmussen, E, Bogner, P, Sable, B, Stienen, S, de Vries, E G E

Get full text

Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP) by van der Velden, D., Hoes, L., van der Wijngaart, H., Bloemendal, H., Grunberg, K., Huitema, A., Lugtenburg, E., De Vos, F., Herpen, C.M.L., de Groot, D.J., Hamberg, P., Smit, E., Cuppen, E., Steeghs, N., Sleijfer, S., Verheul, H.M., Gelderblom, H., Voest, E.

Get full text

Assessment of cfDNA in patients with metastatic colorectal cancer treated with cetuximab monotherapy by Angus, L., van Helden, E.J., van Es, S.C., Boon, E., van Herpen, C.M.L., de Groot, D.J., de Vries, E.G.E., Menke-van der Houven van Oordt, C.W., Sleijfer, S., Verheul, H.M., Jansen, M.P.H.M.

Get full text

89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding by van Oordt, C.W. Menke-van der Houven, van Brummelen, E., Nayak, T., Huisman, M., de Wit- van der Veen, L., Mulder, E., Hoekstra, O., Stokkel, M., van Dongen, G.A., Verheul, H.M., Feilke, M., Guizani, C., Guarin, E., Evers, S., Saro, J., Schellens, J.H.M.

Get full text

Lesion detection by ceCT, 89Zr-girentuximab and FDG PET/CT in newly diagnosed patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) by Verhoeff, S.R., Es, S., Boon, E., van Helden, E., Angus, L., Elias, S., Oosting, S., Aarntzen, E., Brouwers, A., Heskamp, S., Hoekstra, O.S., Verheul, H.M., Van der Veldt, A.A.M., de Vries, E.G.E., Boerman, O., van der Graaf, W.T.A., Oyen, W.J.G., van Herpen, C.M.L.

Get full text

Copy number alterations as predictive biomarkers for response to bevacizumab in metastatic colorectal cancer by van Grieken, N.C., Cordes, M., Verheul, H.M., Neerincx, M., Punt, C., Koopman, M., Meijer, G.A., Murphy, V., Barat, A., Betge, J., Ebert, M., Gaiser, T., Fender, B., Klinger, R., Das, S., Smeets, D., O'Connor, D., Lambrechts, D., Byrne, A.T., Ylstra, B.

Get full text

Treatment and survival of locally advanced pancreatic cancer: A prospective multicenter cohort by Walma, M.S., Brada, L.J., Patuleia, S.I., Rombouts, S.J., Schouten, T.J., Verweij, M.E., De Hingh, I.H., Creemers, G.J., Nederend, J., Stommel, M.W., Radema, S.A., Hermans, J.J., Van Dam, R., De Vos-Geelen, J.M., Van der Leij, C., Liem, M.S., Mekenkamp, L.J., Stassen, E.J., Los, M., Bollen, T.L., Meijerink, M.R., Daams, F., Verheul, H.M., Festen, S., Blomjous, J., Kerver, E.D., Roos, D., Beelen, K.J., Renken, N.S., Bosscha, K., Pruijt, J.F.

Get full text